Premium
Stability of coagulation factors in plasma prepared after a 24‐hour room temperature hold
Author(s) -
Alhumaidan Hiba,
Cheves Tracey,
Holme Stein,
Sweeney Joseph
Publication year - 2010
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2010.02648.x
Subject(s) - fresh frozen plasma , clotting factor , coagulation , chemistry , blood product , blood preservation , clotting time , cryoprecipitate , fibrinogen , medicine , andrology , surgery , platelet , biochemistry
BACKGROUND: The manufacture of fresh‐frozen plasma (FFP) requires that plasma be frozen within 8 hours of collection and 24‐hour frozen plasma requires 1 to 6°C refrigeration before freezing. Manufacture of plasma after a room temperature hold for 24 hours, while convenient, could compromise clotting factor levels. STUDY DESIGN AND METHODS: Pairs of FFP and 24‐hour room temperature–frozen plasma (PLT‐rich plasma [PRP]‐24HRTFP) were manufactured from PRP after a room temperature hold for 8 and 24 hours, respectively. Additional whole blood (WB) donations were kept at room temperature for 24 hours before plasma manufacture (WB‐24HRTFP). The frozen plasma products were stored at −18°C, thawed, and then stored at 1 to 6°C, with coagulation factor assays performed for up to 7 days. RESULTS: On the day of thaw, Factor (F)VIII was lower in PRP‐24HRTFP by 13% (p = 0.002) but not in WB‐24HRTFP (p = 0.3) compared to FFP. All other clotting factors were within normal range. During the postthaw period FVIII and FV declined 25 and 6%, respectively, in WB‐24HRTFP and 23 to 50% in the paired products; however, the difference between both types of 24HRTFP and FFP is insignificant by Day 7 (p > 0.05). Other clotting factors either were unchanged or showed minimal reduction (<15%). CONCLUSION: Plasma manufactured after a 24‐hour room temperature hold contains coagulation factors comparable to FFP except for a possible reduction of up to 20% in FVIII. This plasma appears suitable as a transfusable product and extension of liquid storage to 7 days merits consideration.